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1. Introduction 
Naturally occurring protease inhibitors are proteins 
which inhibit proteolytic enzymes by the formation 
of specific enzyme-inhibitor complexes [ 11. Recently 
it has been observed in several aboratories [2-51 
that many protease inhibitors of plant origin exist in 
solution as dimers, trimers and even tetramers. This 
aggregation phenomenon has complicated the mole- 
cular weight determination of these inhibitors and a 
fortiori the determination of the stoichiometry of 
inhibition. 
Lima bean protease inhibitor (LBI) strongly in- 
hibits both trypsin and chymotrypsin through in- 
dependent combining sites [6,7] . Based on both 
osmotic pressure measurements [8] and amino acid 
analysis [6, 91 its molecular weight is estimated at 
approximately 9000. However, ultracentrifugation 
studies [6, 81 suggest a particle size of nearly twice 
that value. 
In this study an effort was made to establish the 
stoichiometry of interaction between LB1 and bovine 
trypsin and chymotrypsin. The results clearly indicate 
that the monomer of LB1 (M.W. ‘L 9000) can form 1: 1 
molar complexes with either enzyme and also a 
tertiary complex with one mole of each of these two 
enzymes. 
2. Materials and methods 
2.1. Materials 
Lima bean protease inhibitor (LB1 8KB), trypsin 
(TRL OFA), and chymotrypsin (CDI-7CG) were all 
obtained from Worthington (Freehold, N.J.). The in- 
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hibitor was further purified by gel filtration on 
Sephadex G-75 [6,9] . Malic dehydrogenase was 
obtained from Sigma (St. Louis, MO) and ribonuclease 
A and chymotrypsinogen A were obtained from Mann 
(New York, N.Y.). 
2.2. Preparation of complexes 
The inhibitor (30-60 mg) was dissolved in 0.1 M 
NH4HC03 (1-3 ml) first and then the appropriate 
amount of enzyme was dissolved in the inhibitor 
solution. After a 15 min incubation at room tempera- 
ture the mixture was chromatographed on Sephadex 
G-75 under the conditions given in fig. 1. Appro- 
priate fractions were combined and lyophilized. 
2.3. Inhibitor assays 
The inhibitory activities of LB1 and its complexes 
were determined with the spectrophotometric assay 
previously described [7, lo]. N-Benzoyl-L-tyrosine 
ethyl ester and p-tosyl-L-arginine methyl ester were 
used as the synthetic substrates for chymotrypsin and 
trypsin, respectively. 
2.4. Amino acids Qnalysis 
Samples containing 0.05 4.1 pmole of protein 
were hydrolyzed with 6 N HCl at 110” in sealed 
evacuated tubes for 22 hr. The analyses were carried 
out on the Spinco 12OC amino acid analyzer by the 
method of Spa&man [ 1 l] as outlined in the Spinco 
manual. 
2.5. Molecular weight determination 
The molecular weights of LB1 and its complexes 
were estimated by gel filtration on Sephadex G-75 
by the method described by Whitaker [ 121. Samples 
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containing 2-10 mg of protein were dissolved in one 
ml of 0.1 M NH4HC03 and applied to a column 
(1.5 X 85 cm) of Sephadex G-75 equilibrated with the 
same buffer. The flow rate was 11 ml/hr and 1.3 ml 
fractions were collected. 
3. Results and discussion 
3.1. isolation of the complexes 
Fig. 1 illustrates the isolation of the LBI-inhibitor 
complexes by gel filtration. In fig. la peak I has the 
properties expected for the LBI-trypsin complex 
(no trypsin inhibitory activity, high chymotrypsin 
inhibitory activity). Peak I of fig. lb has no chymo- 
trypsin inhibitory activity but still possesses trypsin 
inhibitory activity as expected for the LBI-chymo- 
trypsin complex. Peaks II of fig. la and b have full 
inhibitory activities against both enzymes and re- 
present excess LBI. Peak I of fig. lc has no inhibitory 
activity against either trypsin or chymotrypsin and is 
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Fig. 1. Gel filtration of the complexes of LB1 with trypsin 
and/or chymotrypsin. Columns (2.5 X 90 cm) of Sephadex 
G-75 were equilibrated and developed with 0.1 M NH4HC03. 
Samples ranged from 1-3 ml; the flow rate was 22 ml/hr and 
4.5 ml fractions were collected. Protein was monitored by the 
absorbancy at 280 nm. (a) 40 mg of LB1 to which 100 mg of 
trypsin have been added (b) 30 mg of LB1 to which 50 mg of 
chymotrypsin have been added (c) 50-60 mg of peak I of 
figure 1 a to which 15 mg of chymotrypsin have been added. 
therefore believed to represent the ternary complex 
between LBI, trypsin and chymotrypsin. Peak II of 
fig. lc is believed to be excess LBI-trypsin complex 
(no trypsin inhibitory activity, strong chymotrypsin 
inhibitory activity). An elution profile similar to that 
of fig. lc is also obtained when trypsin is added to an 
excess of peak 1 from fig. lb (LBI-chymotrypsin 
complex). 
3.2. Molecular weight determination 
The results shown in fig. 2 indicate that LB1 has an 
apparent molecular weight of approximately 10,000 
when the sample had a concentration of 2 mg/ml. How- 
ever, this value rose to s 18,000, when the sample 
was applied at concentration of 5 mg/ml. Therefore, 
it appears that LB1 undergoes a concentration depen- 
dent dimerization. The molecular weight of the LBI- 
trypsin complex was calculated to be 32,800. This is 
consistent with the formation of a 1: 1 molar complex 
between enzyme and inhibitor, assuming a molecular 
weight of s 24,000 for the enzyme and % 9,000 for 
the inhibitor. 
3.2. Amino acid analysis 
Table 1 compares the amino composition of the 
LB1 complexes isolated by gel filtration with the 
theoretical amino acid composition based on the 
formation of 1: 1 molar complexes. The agreement, 
within experimental error, between experimental and 
theoretical values proves beyond doubt that LB1 can 
form a 1: 1 molar complex with either trypsin or 
chymotrypsin and can also form a ternary complex 
with one mole of each of these two enzymes. 
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Fig. 2. Molecular weight determination of LB1 and the LBI- 
trypsin complex by gel filtration on Sephadex G-75. (0) ref- 
erence proteins; (0) sample proteins. 
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Table 1 
Amino acid analyses of LBI, chymotrypsin (CT), trypsin (T) and the complexes of LB1 with trypsin (LBI-T), chymotrypsin (LBI- 
CT) and with both trypsin and chymotrypsin (LBI-TC’T)a. 
Amino acid LB1 CT 
LBICT 
T 
LBI-T LB I-T-CT 
Theoryb Experimentc Theoryb Experimentc Theoryb Experimentc 
Lysine 4.17 14.35 18.52 19.16 14.25 18.42 17.10 32.77 34.40 
Histidine 5.37 1.95 7.32 6.52 3.42 8.79 9.90 10.74 11.05 
Arginine 1.95 3.10 5.05 5.05 1.92 3.87 3.82 6.91 8.08 
Aspartic acid 12.80 22.90 35.70 36.20 23.25 36.05 37.90 58.95 59.30 
Threonine 5.09 23.13 28.22 29.42 11.50 16.59 16.19 39.72 38.62 
Serine 11.78 26.50 38.28 39.50 34.75 46.53 47.50 73.03 73.99 
Glutamic acid 6.80 15.50 22.30 23.50 14.90 21.70 22.20 37.20 37.00 
Proline 5.80 10.10 15.90 15.04 9.25 15.05 15.25 25.15 23.70 
Glycine 1.83 24.40 26.23 27.50 27.50 29.33 28.35 53.73 52.49 
Alanine 3.18 23.30 26.38 28.50 14.82 18.00 17.10 41.20 41.60 
Valine 1.30 19.55 20.85 22.80 14.60 15.90 15.74 35.45 34.40 
Methionine - 1.92 1.92 1.85 1.75 1.75 1.82 3.67 2.19 
Isoleucine 3.96 7.20 11.16 11.15 13.25 17.21 18.00 24.40 25.90 
Leucine 2.86 20.75 23.61 25.60 14.00 16.86 17.91 37.61 35.48 
Tyrosine 1.29 4.40 5.69 5.37 11.00 12.29 11.00 16.69 14.39 
Phenylalanine 1.49 6.30 7.79 9.16 2.42 3.91 4.73 10.21 10.95 
a The analyses were carried out as described in the text. The results are expressed as moles/mole and have not been corrected for 
destruction of residues by acid hydrolysis. 
b The theoretical values were obtained by adding the amino acid compositions of enzyme and inhibitor, assuming the formation 
of 1: 1 molar complexes. 
e The experimental values were obtained by amino acid analysis of the isolated complexes. 
It is known that, when assayed with synthetic sub- 
strates, 1 mg of LB1 inhibits approximately 2.5 mg of 
trypsin and 1.0-l .5 mg of chymotrypsin [6, 71. The 
amount of trypsin inhibited is in agreement with the 
formation of a 1: 1 molar complex, but the amount of 
chymotrypsin is less than expected for a 1: 1 molar 
complex. We believe that this is due to a displacement 
of chymotrypsin from the LBIchymotrypsin complex 
by the substrate (benzoyl-L-tyrosine ethylester). This 
is substantiated by the fact that in the assay system 
used, both LBI-chymotrypsin and the ternary complex 
show considerable chymotryptic activity. 
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